Related Experiment Videos
Mutations in cardiac sodium channels: clinical implications
Huajun Liu1, Colleen Clancy, Joseph Cormier
1Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|June 20, 2003
Summary
Mutations in cardiac sodium channels (SCN5A) cause heart rhythm disorders. Flecainide shows promise for treating Long QT syndrome and Brugada syndrome, but its effectiveness depends on specific SCN5A mutations.
Area of Science:
- Cardiovascular physiology
- Molecular biology
- Pharmacology
Background:
- Voltage-gated sodium channels (VGSCs) are crucial for cardiac action potentials.
- Mutations in SCN5A cause Long QT syndrome (LQT-3), Brugada syndrome (BrS), and cardiac conduction disease.
- Understanding these mutations is key to managing inherited arrhythmia syndromes.
Purpose of the Study:
- To investigate the differential sensitivity of SCN5A mutant channels to local anesthetics like flecainide.
- To explore the mechanisms underlying flecainide's efficacy in LQT-3 and BrS.
- To determine if flecainide's effects are mutation-specific.
Main Methods:
- Electrophysiological studies of wild-type and mutant VGSCs (D1790G, Y1795H, Y1795C).
- Assessment of channel block by flecainide and lidocaine.
- Analysis of drug access based on channel gating and inactivation properties.
Main Results:
- LQT-3 (D1790G) and BrS (Y1795H) mutant channels show increased flecainide sensitivity compared to wild-type.
- Lidocaine sensitivity remains unchanged across all tested channels.
- One LQT-3 mutant (Y1795C) exhibits no change in flecainide sensitivity.
Conclusions:
- Flecainide's therapeutic effect on SCN5A-related channelopathies is mutation-dependent.
- Altered channel inactivation in mutants enhances flecainide binding.
- Flecainide offers a promising, albeit mutation-specific, treatment strategy for certain cardiac arrhythmias.